Novo Nordisk's (NVO) stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.
The company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billion. Wegovy sales more than doubled to $2.77 billion, while Ozempic sales rose 12% to $4.74 billion, both beating forecasts.
Novo Nordisk's robust financial results were fueled by the soaring demand for its innovative GLP-1 drugs, which have been widely embraced by healthcare providers and patients alike. However, the company acknowledged that it expects periodic supply constraints and related drug shortage notifications across several products and geographies in 2025, as it grapples with the challenges of meeting the surging demand.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。